Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic acid for Perthes disease
ACTRN12610000407099Phase 2Recruiting
- Sponsor
- The Children's Hospital at Westmead
- Start
- Jan 2011
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of zoledronic acid in Legg-Calvé-Perthes disease (LCPD) (2 arms), sponsored by The Children's Hospital at Westmead. Primary endpoint: Femoral head sphericity. Started Jan 2011; status: recruiting.
02
Drugs
zoledronic acid
03
Conditions
Legg-Calvé-Perthes disease (LCPD)
Beyond the preview
Go deeper on ACTRN12610000407099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610000407099.